A recombinant BHV-1 oncolytic virus is provided comprising a BHV-1 mutant with enhanced cancer selectivity and/or enhance immunostimulatory activity as compared to wildtype BHV-1. The BHV-1 mutant is genetically modified to express one or more immunomodulatory molecules that induce an anti-tumor immune response. A method of generating the recombinant BHV-1 oncolytic virus is also provided.

The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.

Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.

Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.

Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.

A pseudorabies virus (PRV) or a modified form thereof, or a genome sequence or a cDNA sequence containing the PRV or the modified form thereof, or nucleic acid molecules of a complementary sequence of the cDNA sequence, for treating tumors of subjects and/or reducing or inhibiting tumor recurrence, and for preparation of a pharmaceutical composition used for treating the tumors of the subjects and/or reducing or inhibiting the tumor recurrence. A method for treating tumors and/or reducing or inhibiting tumor recurrence, comprising a step of administering, on a subject having a need, the PRV or the modified form thereof, or nucleic acid molecules of the genome sequence containing the PRV or the modified form thereof.

Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.

Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.

Provided herein are compositions and methods for vaccination and research applications. In particular, provided herein are non-neuroinvasive herpesviruses and alpha herpesviruses and uses thereof.

The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.